Andrew J Godkin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3310498/publications.pdf

Version: 2024-02-01

88 papers	5,189 citations	87723 38 h-index	91712 69 g-index
90 all docs	90 docs citations	90 times ranked	8768 citing authors

#	Article	IF	Citations
1	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	2.8	119
2	Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. Journal of Clinical Immunology, 2022, 42, 32-35.	2.0	15
3	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	2.0	21
4	Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances, 2022, 2, ltab025.	1.2	26
5	Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 64, 103937.	0.9	18
6	The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity. Trends in Cancer, 2021, 7, 214-225.	3.8	28
7	Molecular characterization of HLA class II binding to the LAGâ€3 T cell coâ€inhibitory receptor. European Journal of Immunology, 2021, 51, 331-341.	1.6	13
8	Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer, 2021, 124, 1552-1555.	2.9	2
9	Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology, 2021, 163, 389-398.	2.0	5
10	VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium. Nucleic Acids Research, 2020, 48, D1057-D1062.	6.5	268
11	Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. Cancer Immunology Research, 2020, 8, 1520-1531.	1.6	16
12	Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy. Molecular Therapy - Oncolytics, 2020, 18, 443-456.	2.0	9
13	CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Cell Reports, 2020, 32, 107885.	2.9	11
14	Elevated interleukinâ€6, interleukinâ€10 and neutrophilÂ:Âlymphocyte ratio as identifiers of severe coronavirus disease 2019. Immunology, 2020, 160, 221-222.	2.0	5
15	Enhanced antitumor immunity through sequential targeting of PI3KÎ´ and LAG3. , 2020, 8, e000693.		22
16	Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy, 2020, 69, 2063-2073.	2.0	9
17	Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells. Clinical Cancer Research, 2020, 26, 3360-3370.	3.2	3
18	The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology, 2019, 19, 98.	0.8	72

#	Article	IF	Citations
19	Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry, 2019, 294, 20246-20258.	1.6	10
20	TCRâ€induced alteration of primary MHC peptide anchor residue. European Journal of Immunology, 2019, 49, 1052-1066.	1.6	23
21	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Reports, 2019, 1, 437-445.	2.6	48
22	The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy, 2019, 68, 247-256.	2.0	10
23	Tâ€cell modulation by cyclophosphamide for tumour therapy. Immunology, 2018, 154, 62-68.	2.0	53
24	In Silico and Structural Analyses Demonstrate That Intrinsic Protein Motions Guide T Cell Receptor Complementarity Determining Region Loop Flexibility. Frontiers in Immunology, 2018, 9, 674.	2.2	26
25	Chronic infections with viruses or parasites: breaking bad to make good. Immunology, 2017, 150, 389-396.	2.0	13
26	Treg Depletion Licenses T Cellâ€“Driven HEV Neogenesis and Promotes Tumor Destruction. Cancer Immunology Research, 2017, 5, 1005-1015.	1.6	78
27	Effect of Modified Vaccinia Ankaraâ€“5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, e172579.	3.4	51
28	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 6771-6780.	3.2	114
29	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology, 2017, 35, 154-154.	0.8	1
30	Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5682-5687.	3.3	51
31	The Peptide Ligands Presented by MHC Class II Molecules. , 2016, , 209-214.		1
32	Cytomegalovirus-Specific IL-10-Producing CD4+ T Cells Are Governed by Type-I IFN-Induced IL-27 and Promote Virus Persistence. PLoS Pathogens, 2016, 12, e1006050.	2.1	46
33	Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptideâ€“MHC Class II Multimers. Journal of Immunology, 2015, 195, 5827-5836.	0.4	12
34	More tricks with tetramers: a practical guide to staining T cells with peptideâ€“<scp>MHC</scp> multimers. Immunology, 2015, 146, 11-22.	2.0	106
35	A distinct chemokine axis does not account for enrichment of Foxp3⁺Â<scp>CD</scp>4⁺ T cells in carcinogenâ€induced fibrosarcomas. Immunology, 2015, 145, 94-104.	2.0	9
36	High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology, 2015, 4, e974374.	2.1	60

#	Article	IF	Citations
37	Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	14
38	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy, 2015, 64, 1271-1286.	2.0	161
39	Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods, 2015, 424, 131-135.	0.6	15
40	Structural basis for ineffective Tâ€cell responses to MHC anchor residueâ€improved â€œheteroclticâ€• peptides. European Journal of Immunology, 2015, 45, 584-591.	1.6	63
41	Antibody Stabilization of Peptideâ€“MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. Journal of Immunology, 2015, 194, 463-474.	0.4	55
42	Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget, 2015, 6, 24649-24659.	0.8	16
43	Progression of carcinogenâ€induced fibrosarcomas is associated with the accumulation of naÃ¯ve CD4+ T cells via blood vessels and lymphatics. International Journal of Cancer, 2014, 134, 2156-2167.	2.3	7
44	T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions. Journal of Biological Chemistry, 2014, 289, 628-638.	1.6	63
45	The paradox of NKp46⁺natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon Î± treatment. Gut, 2014, 63, 515-524.	6.1	54
46	Interleukinâ€6 limits influenzaâ€induced inflammation and protects against fatal lung pathology. European Journal of Immunology, 2013, 43, 2613-2625.	1.6	143
47	Epithelial Barriers, Microbiota, and Colorectal Cancer. New England Journal of Medicine, 2013, 368, 282-284.	13.9	47
48	Flow cytometry makes all the difference. Journal of Hepatology, 2013, 59, 909-910.	1.8	0
49	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. Frontiers in Immunology, 2013, 4, 197.	2.2	70
50	Re-Directing CD4+ T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. Frontiers in Immunology, 2013, 4, 172.	2.2	58
51	Rapid innate control of antigen abrogates adaptive immunity. Immunology, 2013, 138, 293-297.	2.0	2
52	High endothelial venules. OncoImmunology, 2013, 2, e24272.	2.1	4
53	Escalating Regulation of 5T4-Specific IFN-Î³+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy. Cancer Immunology Research, 2013, 1, 416-425.	1.6	15
54	T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion. Cancer Research, 2012, 72, 5473-5482.	0.4	97

#	Article	IF	Citations
55	Hunting for clues. OncoImmunology, 2012, 1, 1163-1164.	2.1	0
56	Suppression of tumour-specific CD4⁺T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut, 2012, 61, 1163-1171.	6.1	127
57	Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications, 2012, 3, 665.	5.8	36
58	Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Scientific Reports, 2012, 2, 629.	1.6	26
59	Avidity of influenzaâ€specific memory <scp>CD</scp>8⁺<scp>T</scp>â€cell populations decays over time compromising antiviral immunity. European Journal of Immunology, 2012, 42, 3235-3242.	1.6	3
60	T cell subsets and colorectal cancer: Discerning the good from the bad. Cellular Immunology, 2012, 279, 21-24.	1.4	17
61	Rapid early innate control of hepatitis C virus during IFN â€Î± treatment compromises adaptive CD 4 + T â€cell immunity. European Journal of Immunology, 2012, 42, 2383-2394.	1.6	15
62	Setting the threshold for extraâ€thymic differentiation of Foxp3⁺ Tregs: TGFâ€Î²â€dependent and Tâ€cell autonomous. European Journal of Immunology, 2011, 41, 1218-1220.	1.6	0
63	Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptideâ€“MHCI Tetramer Staining. Journal of Immunology, 2011, 187, 654-663.	0.4	34
64	Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax, 2011, 66, 368-374.	2.7	39
65	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors. Cancer Research, 2011, 71, 736-746.	0.4	112
66	Clinical characteristics of hepatitis E in a â€œNonâ€Endemicâ€•population. Journal of Medical Virology, 2010, 82, 1899-1902.	2.5	20
67	Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology, 2010, 131, 583-592.	2.0	47
68	Type I Interferon (IFNÎ±) Acts Directly on Human Memory CD4+T Cells Altering Their Response to Antigen. Journal of Immunology, 2009, 183, 2915-2920.	0.4	38
69	CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?. Journal of Immunology, 2009, 182, 5203-5207.	0.4	46
70	Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods, 2009, 340, 11-24.	0.6	134
71	Latent viral infections in critically ill patients. Critical Care, 2009, 13, 410.	2.5	0
72	Regulatory T cells and tumour immunity â€“ observations in mice and men. Immunology, 2008, 123, 157-163.	2.0	94

#	Article	IF	Citations
73	Expansion of hepatitis Câ€“specific CD4+CD25+ regulatory T cells after viral clearance: A mechanism to limit collateral damage?. Journal of Allergy and Clinical Immunology, 2008, 121, 1277-1284.e3.	1.5	17
74	Interleukin-6 Is Crucial for Recall of Influenza-Specific Memory CD4+ T Cells. PLoS Pathogens, 2008, 4, e1000006.	2.1	89
75	A case of persistent anemia and alcohol abuse. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 521-526.	1.7	14
76	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. European Journal of Immunology, 2007, 37, 758-767.	1.6	25
77	Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology, 2007, 37, 798-806.	1.6	30
78	CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer. PLoS ONE, 2006, 1, e129.	1.1	183
79	Regulating the immune response to tumours. Advanced Drug Delivery Reviews, 2006, 58, 948-961.	6.6	51
80	T-Cell Costimulation. New England Journal of Medicine, 2006, 355, 2594-2595.	13.9	8
81	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 2005, 41, 1383-1390.	3.6	125
82	Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus. Journal of Immunology, 2002, 169, 2210-2214.	0.4	99
83	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. European Journal of Immunology, 2001, 31, 1438-1446.	1.6	60
84	Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions. Journal of Immunology, 2001, 166, 6720-6727.	0.4	125
85	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nature Medicine, 2000, 6, 337-342.	15.2	521
86	The pathogenesis of celiac disease. Gastroenterology, 1998, 115, 206-210.	0.6	91
87	Induction and Exhaustion of Lymphocytic Choriomeningitis Virusâ€“specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class Iâ€“Peptide Complexes. Journal of Experimental Medicine, 1998, 187, 1383-1393.	4.2	688
88	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics, 1997, 45, 229-232.	1.2	15